AU648792B2 - Creation of Inventions and Patents with Artificial Intelligence

AU648792B2 – Veterinary treatment for pigs
– Google Patents

AU648792B2 – Veterinary treatment for pigs
– Google Patents
Veterinary treatment for pigs

Info

Publication number
AU648792B2

AU648792B2
AU77581/91A
AU7758191A
AU648792B2
AU 648792 B2
AU648792 B2
AU 648792B2
AU 77581/91 A
AU77581/91 A
AU 77581/91A
AU 7758191 A
AU7758191 A
AU 7758191A
AU 648792 B2
AU648792 B2
AU 648792B2
Authority
AU
Australia
Prior art keywords
veterinarily acceptable
amoxycillin
pigs
treatment
clavulanic acid
Prior art date
1990-04-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Application number
AU77581/91A
Other versions

AU7758191A
(en

Inventor
Victor Charles Cracknell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Inc

Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1990-04-26
Filing date
1991-04-22
Publication date
1994-05-05
Family has litigation

First worldwide family litigation filed
litigation
Critical
https://patents.darts-ip.com/?family=10675074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU648792(B2)
“Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-04-22
Application filed by Beecham Group PLC
filed
Critical
Beecham Group PLC

1991-11-11
Publication of AU7758191A
publication
Critical
patent/AU7758191A/en

1994-05-05
Application granted
granted
Critical

1994-05-05
Publication of AU648792B2
publication
Critical
patent/AU648792B2/en

1997-09-18
Assigned to PFIZER INC.
reassignment
PFIZER INC.
Alteration of Name(s) in Register under S187
Assignors: BEECHAM GROUP PLC

2011-04-22
Anticipated expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K31/00—Medicinal preparations containing organic active ingredients

A61K31/33—Heterocyclic compounds

A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins

A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

A61K31/425—Thiazoles

A61K31/429—Thiazoles condensed with heterocyclic ring systems

A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P15/00—Drugs for genital or sexual disorders; Contraceptives

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A formulation comprising amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier is used in the treatment of farrowing fever and/or bacterial pneumonia in pigs.

Description

Veterinary Treatment
This invention relates to a method for the treatment of bacterial infections in pigs, particularly those infections associated with farrowing fever and bacterial pneumonia.
GB-B-2 005 538 describes a dry pharmaceutical composition, which comprises 20mg to 1500mg of amoxycillin trihydrate, 20mg to 500mg of potassium clavulanate and a pharmaceutically acceptable carrier, with the proviso that the weight ratio of amoxycillin trihydrate to potassium clavulanate is from 6:1 to 1:1.
According to the present invention there is provided a method for the treatment of farrowing fever and bacterial pneumonia in pigs, which comprises administering to the animal an effective amount of amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier.
A second aspect of the invention provides the use of a formulation comprising an effective amount of amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier in the manufacture of a medicament for use in the treatment of farrowing fever and bacterial pneumonia in pigs.
The formulation has notable bactericidal activity against the bacteria associated with the diseases farrowing fever and bacterial pneumonia in particular
SUBSTITUTE SHEET

Actinobacillus pleuropneumoniae.
Suitably the clavulanic acid used in the formulation is in the form of a veterinarily acceptable salt such as potassium clavulanate.
Suitably the amoxycillin used in the formulation is in the form of the trihydrate or a veterinarily acceptable ester or salt of amoxycillin such as the sodium salt.
The preferred weight ratio of amoxycillin or derivative to clavulanic acid or derivative is from 6:1 to 1:1.
Advantageously, a liquid formulation of the invention comprises 36mg/ml clavulanic acid (as potassium clavulanate) and 140mg/ml amoxycillin (as amoxycillin trihydrate) .
Preferred veterinarily acceptable carriers include for example veterinarily acceptable oils such as mineral oils or fractionated coconut oil such as Miglyol 840.
Suitably the formulation is administered to the animal by intramuscular injection.
The formulation is typically prepared as an off-white suspension and is presented as a ‘Ready-To-Use’ form, that is the formulation is preprepared and packed in a suitable container, wherein it is ready for administration to the animal in need thereof.
The dosage rate will vary according to the size of the animal. A suitable dosage rate is generally between 2 and 25mg/kg bodyweight of the animal, for example about 8.75mg/kg.
SUBSTITUTE SHEET

Typically more than a single dose of the formulation will be required for the treatment of the bacterial infections, suitably one dose per day for 3 to 5 days is required. In cases of severe infections prolonged treatment may be required.
Veterinary formulations for use in the present invention may be prepared by mixing the ingredients thereof in the required proportions.
The formulation is then packaged into an appropriate container ready for administration.
The following Example illustrates the invention.
Formulation g/lOOml
amoxycillin trihydrate 14.0 potassium clavulanate 3.6 phenol 0.5 iglyol 840 to 100ml
SUBSTITUTESHEET

Clinical data
CASE STUDY 1
Naturally-occuring cases of farrowing fever in pigs were diagnosed on clinical grounds, then treated on an alternating basis with either Synulox* or a control drug. The control drug was a penicillin G/streptomycin mixture. Treatment was administered once daily for a minimum of 3 days. Synulox* was given at a dose rate of 1ml per 20kg of body weight.
The clinical response to treatment was scored on a pre-defined scale:
CRS 1 = excellent
CRS 2 = food
CRS 3 = fair
CRS 4 *= poor
(CRS = clinical response score)
From the results which are summarised in FIG 1, it can be seen that Synulox* has good efficacy in the treatment of farrowing fever in pigs.
SUBSTITUTE SHEET

CASE STUDY 2
A total of 229 pigs with pneumonia caused by Actinobacillus (Haemophilus) pleuropneumonia were involved in this study.
156 pigs were treated with Synulox* and 73 were treated with a control drug, oxytetracycline (lml/kg body weight administered intramuscularly) . Synulox* was injected intramuscularly at a dose rate of lml/20kg body weight. Treatment was continued daily until clinical signs of cough, dyspnoea, anorexia and depression were remitted and clinical responses were stored on the basis of the number of treatments required to achieve remissision. Clinical response was scored as follows:
CRS 1 = excellent CRS 2 = good CRS 3 = fair CRS 4 = poor
The clinical response scores are summarised in FIG 2, wherein it was shown that of the total of 156 pigs treated with Synulox* 48.1% showed an ‘ ‘excellent’ ‘ response, 31.4% had a ”good” response, 18.6% ”fair” and only 1.9% ”poor” against 35.6% of pigs treated with the control showing an ”excellent” response 32.9%, ”good”, 31.5% ”fair” and 0% ”poor”. It was therefore concluded that Synulox* has good efficacy in the treatment of bacterial pneumonia in pigs.
* Synulox is a Trademark of Beecham Group p.I.e.
Synulox is an oily suspension contining 35mg/ml clavulanic acid (K salt) and 140mg/ml amoxycillin (trihydrate) .
SUBSTITUTE SHEET

Claims (7)

Claims

1. The use of a formulation comprising an effective amount of amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier in the manufacture of a medicament for use in the treatment of farrowing fever and/or bacterial pneumonia in pigs.

2. A method for the treatment of farrowing fever and/or bacterial pneumonia in pigs, which comprises administering to the animal an effective amount of amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier.

3. A veterinary composition for the treatment of farrowing fever and/or bacterial pneumonia in pigs, which comprises an effective amount of amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier.

4. The use according to claim 1 wherein the clavulanic acid is used in the form of potassium clavulanate.

5. The use according to claim 1 or 4 wherein the amoxycillin is used in the form of the trihydrate or the sodium salt.

6. The use according to claim 1, 4 or 5 wherein the weight ratio of amoxycillin or derivative to clavulanic acid or derivative is from 6:1 to 1:1.
SUBSTITUTE SHEET

7. The use according to claim 1, 4, 5 or 6 wherein the veterinarily acceptable carrier is an oil suitable for injection.
SUBSTITUTE SHEET

AU77581/91A
1990-04-26
1991-04-22
Veterinary treatment for pigs

Expired

AU648792B2
(en)

Applications Claiming Priority (3)

Application Number
Priority Date
Filing Date
Title

GB9009446

1990-04-26

GB909009446A

GB9009446D0
(en)

1990-04-26
1990-04-26
Veterinary composition

PCT/GB1991/000635

WO1991016050A1
(en)

1990-04-26
1991-04-22
Veterinary treatment

Publications (2)

Publication Number
Publication Date

AU7758191A

AU7758191A
(en)

1991-11-11

AU648792B2
true

AU648792B2
(en)

1994-05-05

Family
ID=10675074
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU77581/91A
Expired

AU648792B2
(en)

1990-04-26
1991-04-22
Veterinary treatment for pigs

Country Status (15)

Country
Link

EP
(1)

EP0607122B1
(en)

JP
(1)

JPH05506237A
(en)

KR
(1)

KR100203704B1
(en)

AT
(1)

ATE203160T1
(en)

AU
(1)

AU648792B2
(en)

CA
(1)

CA2081348C
(en)

DE
(1)

DE69132663T2
(en)

DK
(1)

DK0607122T3
(en)

ES
(1)

ES2157888T3
(en)

GB
(1)

GB9009446D0
(en)

GR
(1)

GR3036905T3
(en)

IE
(1)

IE911398A1
(en)

NZ
(1)

NZ237931A
(en)

WO
(1)

WO1991016050A1
(en)

ZA
(1)

ZA913073B
(en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

GB9007143D0
(en)

1990-03-30
1990-05-30
Beecham Group Plc
Veterinary composition

US5324840A
(en)

1992-06-11
1994-06-28
Allergan, Inc.
Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects

Citations (2)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

GB2005538A
(en)

1977-10-11
1979-04-25

Beecham Group Ltd

Compositions containing amoxycillin trihydrate and potassium clavulanate

AU7570891A
(en)

1990-03-30
1991-10-30

Pfizer Inc.

Veterinary treatment of lambs and sheep

Family Cites Families (4)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US1508977A
(en)

1924-01-19
1924-09-16
John Armstrong Hume
Advertising device

US4529720A
(en)

1974-04-20
1985-07-16
Beecham Group, P.L.C.
Antibiotic from Streptomyces clavulicerus

IE41109B1
(en)

1974-04-20
1979-10-24
Beecham Group Ltd
Novel -lactam antibiotic from streptomyces clavuligerus

IL58461A0
(en)

1978-10-27
1980-01-31
Beecham Group Ltd
Intramammary compositions comprising a clavulanic acid salt

1990

1990-04-26
GB
GB909009446A
patent/GB9009446D0/en
active
Pending

1991

1991-04-22
JP
JP91508210A
patent/JPH05506237A/en
active
Pending

1991-04-22
CA
CA002081348A
patent/CA2081348C/en
not_active
Expired – Lifetime

1991-04-22
WO
PCT/GB1991/000635
patent/WO1991016050A1/en
not_active
Application Discontinuation

1991-04-22
AT
AT91908740T
patent/ATE203160T1/en
not_active
IP Right Cessation

1991-04-22
EP
EP91908740A
patent/EP0607122B1/en
not_active
Revoked

1991-04-22
DE
DE69132663T
patent/DE69132663T2/en
not_active
Revoked

1991-04-22
AU
AU77581/91A
patent/AU648792B2/en
not_active
Expired

1991-04-22
ES
ES91908740T
patent/ES2157888T3/en
not_active
Expired – Lifetime

1991-04-22
KR
KR1019920702637A
patent/KR100203704B1/en
not_active
IP Right Cessation

1991-04-22
DK
DK91908740T
patent/DK0607122T3/en
active

1991-04-24
ZA
ZA913073A
patent/ZA913073B/en
unknown

1991-04-24
NZ
NZ237931A
patent/NZ237931A/en
unknown

1991-04-25
IE
IE139891A
patent/IE911398A1/en
not_active
IP Right Cessation

2001

2001-10-16
GR
GR20010401775T
patent/GR3036905T3/en
not_active
IP Right Cessation

Patent Citations (2)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

GB2005538A
(en)

1977-10-11
1979-04-25
Beecham Group Ltd
Compositions containing amoxycillin trihydrate and potassium clavulanate

AU7570891A
(en)

1990-03-30
1991-10-30
Pfizer Inc.
Veterinary treatment of lambs and sheep

Also Published As

Publication number
Publication date

ES2157888T3
(en)

2001-09-01

WO1991016050A1
(en)

1991-10-31

CA2081348A1
(en)

1991-10-27

DK0607122T3
(en)

2001-09-24

CA2081348C
(en)

2001-12-25

KR100203704B1
(en)

1999-06-15

DE69132663D1
(en)

2001-08-23

JPH05506237A
(en)

1993-09-16

EP0607122A1
(en)

1994-07-27

EP0607122B1
(en)

2001-07-18

KR930700100A
(en)

1993-03-13

ATE203160T1
(en)

2001-08-15

GB9009446D0
(en)

1990-06-20

NZ237931A
(en)

1992-04-28

GR3036905T3
(en)

2002-01-31

AU7758191A
(en)

1991-11-11

DE69132663T2
(en)

2001-10-31

IE911398A1
(en)

1991-11-06

ZA913073B
(en)

1992-03-25

Contact information